Not Medical Advice: This page summarizes published clinical research for educational purposes. It does not constitute medical advice. Drug efficacy and safety in any individual patient depend on factors that should be evaluated by a licensed healthcare provider.
How GLP-1 Receptor Agonists Work
GLP-1 (glucagon-like peptide-1) is an incretin hormone released by L-cells in the small intestine within minutes of food ingestion. Native human GLP-1 has an extremely short half-life of about 2 minutes due to rapid degradation by the enzyme DPP-4. GLP-1 receptor agonist medications are engineered analogs that resist DPP-4 degradation, dramatically extending their duration of action while preserving the natural physiological effects.
Glucose-Dependent Insulin Secretion
GLP-1 binds to GLP-1 receptors (GLP-1R) on pancreatic β-cells, triggering increased insulin secretion in response to elevated blood glucose. Critically, this effect is glucose-dependent — meaning insulin is only released when glucose is high. This is why GLP-1s rarely cause hypoglycemia as monotherapy, unlike sulfonylureas.
Drucker DJ. Cell Metab. 2018 · PMID 29617641Suppression of Glucagon
GLP-1 simultaneously inhibits glucagon secretion from pancreatic α-cells. Lowering glucagon reduces hepatic glucose production, contributing to better fasting glucose levels. This dual β/α-cell effect is why GLP-1s are so effective in type 2 diabetes management.
Nauck MA. Diabetes Care. 2016 · PMID 27084342Delayed Gastric Emptying
GLP-1 slows gastric emptying through vagal nerve signaling. This prolongs satiety after meals (you feel full longer) and flattens postprandial glucose excursions. The slowing effect is most pronounced early in treatment and partially attenuates over time. This mechanism is also responsible for many of the GI side effects seen with GLP-1s — particularly nausea during dose escalation.
Marathe CS. Diabetes Care. 2013 · PMID 23613602Hypothalamic Appetite Suppression
GLP-1 receptors are expressed in the arcuate nucleus of the hypothalamus, where GLP-1 agonists directly suppress appetite-stimulating NPY/AgRP neurons and activate appetite-suppressing POMC/CART neurons. This central effect is the primary driver of weight loss with GLP-1 therapy — patients eat less because they feel less hungry, not just because they get full faster.
Secher A. J Clin Invest. 2014 · PMID 25036908Tirzepatide's Additional GIP Pathway
Tirzepatide is unique because it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, in addition to GLP-1 receptors. GIP signaling appears to potentiate the insulinotropic effect of GLP-1, may enhance lipid metabolism, and may reduce some of the nausea associated with pure GLP-1 agonism. The dual-agonism mechanism is widely credited as the reason tirzepatide produces 50% greater weight loss than semaglutide head-to-head.
Frías JP. NEJM 2021 (SURPASS-2) · PMID 34170647Cardiovascular & Renal Pleiotropic Effects
GLP-1 receptors are also expressed in cardiovascular tissue, kidney, and brain — explaining the broader benefits seen in outcomes trials. GLP-1 agonism reduces vascular inflammation, improves endothelial function, lowers blood pressure modestly, and reduces albuminuria. These effects appear to be at least partially independent of weight loss and glycemic control.
Sattar N. Lancet Diabetes Endocrinol. 2021 · PMID 34216544The Studies That Defined GLP-1 Therapy
Every GLP-1 medication in U.S. practice today is FDA-approved based on randomized controlled trials of thousands of patients. Here are the most important.
Once-Weekly Semaglutide for Obesity
Established semaglutide 2.4mg weekly as effective for weight loss in adults with overweight or obesity without diabetes. Mean placebo-subtracted weight loss was -12.4%, the largest ever seen for a non-surgical weight loss medication at that time.
(semaglutide arm)
Tirzepatide Once Weekly for Obesity
Established tirzepatide as the most effective weight loss medication ever brought to market. Patients on the 15mg dose lost an average of 22.5% of body weight, with 36% losing more than 25%.
(15mg arm)
Tirzepatide vs Semaglutide Direct Comparison
First and only head-to-head trial of tirzepatide vs semaglutide. Tirzepatide 15mg produced significantly greater weight loss (-11.2 kg) than semaglutide 1mg (-5.7 kg), and superior HbA1c reduction (-2.30% vs -1.86%).
Liraglutide 3.0mg for Weight Management
The original FDA-approval trial for liraglutide as a weight loss medication (Saxenda). Established a mean -8.0% weight loss vs placebo and the safety profile that defined GLP-1 therapy for the next decade.
Semaglutide CV Outcomes in Obesity Without Diabetes
Landmark trial demonstrating that semaglutide reduces cardiovascular events in patients with obesity but without diabetes. The first GLP-1 to show CV benefit independent of glucose lowering — a paradigm-shifting finding for obesity medicine.
Semaglutide for Diabetic Kidney Disease
Stopped early due to overwhelming benefit. Semaglutide reduced the composite endpoint of kidney failure, sustained ≥50% eGFR decline, or death from kidney/CV causes by 24% in patients with T2D and CKD.
Liraglutide and Cardiovascular Outcomes
First GLP-1 to demonstrate cardiovascular outcome benefit. Liraglutide reduced major adverse cardiovascular events by 13% in patients with T2D and high CV risk. This trial opened the door for the cardiometabolic positioning of GLP-1s.
Tirzepatide for Obstructive Sleep Apnea
Led to FDA approval of tirzepatide as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity. Mean reduction in apnea-hypopnea index exceeded 50% at the 15mg dose.
All 22 Peer-Reviewed References
Every clinical claim on GLPOneReview.com is supported by peer-reviewed sources. PMIDs are provided for direct verification on PubMed.
Editorial Note: All references are publicly indexed on PubMed. We periodically update this page when new landmark trials are published. If you spot an error in any citation, please report it via our contact page. View provider standards →
Disclosures Regarding Compounded GLP-1 Medications
FDA status of compounded medications. Several providers reviewed on this site facilitate access to compounded semaglutide or compounded tirzepatide. Compounded medications are not FDA-approved and have not been evaluated by the U.S. Food and Drug Administration for safety, effectiveness, or quality. Compounded semaglutide is not the same as Ozempic® or Wegovy®, and compounded tirzepatide is not the same as Mounjaro® or Zepbound®. None of the providers reviewed on this site are affiliated with Novo Nordisk or Eli Lilly.
Pharmacy sourcing. When prescribed by a licensed provider and clinically appropriate, compounded GLP-1 medications are typically prepared by U.S.-licensed compounding pharmacies operating under state board oversight and applicable sterile compounding standards, including USP <797>. Some formulations are sourced from FDA-registered 503B outsourcing facilities operating under current good manufacturing practices (cGMP); others are fulfilled by licensed 503A pharmacies based on provider direction, pharmacy availability, patient location, and applicable law. Product appearance, concentration, and packaging may vary by pharmacy.
Outcomes. Individual results vary. No provider reviewed on this site guarantees weight loss, treatment success, clinical outcomes, or medication eligibility. Outcomes depend on adherence, provider guidance, lifestyle changes, metabolic health, underlying conditions, and consistency with the care plan.
Service availability. Telehealth services are available only to individuals physically located in U.S. states where affiliated providers are licensed and pharmacy fulfillment is legally permitted. Service availability, medication access, consultation requirements, pharmacy options, and features may change based on regulatory and operational factors.